CADL - Spark Newswire

5 minute read

60 Biggest Movers From Yesterday

Today, 4:46 PM

Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value of $2.26 billion.

ABVC

2 minute read

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

Today, 4:46 PM

ALIM

3 minute read

35 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 4:46 PM

Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares climbed 187.8% to $17.53 after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value of $2.26 billion.

ALXO

4 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For August 23, 2021

By Benzinga Insights

Today, 4:46 PM

Upgrades JP Morgan upgraded the previous rating for Pearson PLC (NYSE:PSO) from Neutral to Overweight. The current stock performance of Pearson shows a 52-week-high of $12.38 and a 52-week-low of $6.13. Moreover, at the end of the last trading period, the closing price was at $10.41.

ACVA

1 minute read

UBS Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $9

By Benzinga Newsdesk

Today, 4:46 PM

UBS analyst Colin Bristow initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $9.

CADL

1 minute read

Jefferies Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

By Benzinga Newsdesk

Today, 4:46 PM

Jefferies analyst Chris Howerton initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $22.

CADL

1 minute read

Credit Suisse Initiates Coverage On Candel Therapeutics with Outperform Rating, Announces Price Target of $15

By Benzinga Newsdesk

Today, 4:46 PM

Credit Suisse analyst Judah Frommer initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Outperform rating and announces Price Target of $15.

CADL

6 minute read

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data

By Shanthi Rexaline

Today, 4:46 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19)

ABVC

6 minute read

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline

By Shanthi Rexaline

Today, 4:46 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)

ABBV

3 minute read

The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow

By Shanthi Rexaline

Today, 4:46 PM

Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among those reporting during the week.

ABSI

Feed Symbols: CADL